ATRACURIUM BESYLATE injection solution Estats Units - anglès - NLM (National Library of Medicine)

atracurium besylate injection solution

aurobindo pharma limited - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate 50 mg in 5 ml

ATRACURIUM BESYLATE powder Estats Units - anglès - NLM (National Library of Medicine)

atracurium besylate powder

attix pharmaceuticals inc - atracurium besylate (unii: 40ax66p76p) (atracurium besylate - unii:40ax66p76p) - atracurium besylate 25 kg in 25 kg

Atracurium besilate 10 mg/ml solution for injection/infusion Irlanda - anglès - HPRA (Health Products Regulatory Authority)

atracurium besilate 10 mg/ml solution for injection/infusion

as kalceks - atracurium besilate - solution for injection/infusion - 10 milligram(s)/millilitre - other quaternary ammonium compounds; atracurium

ATRACURIUM BESYLATE- atracurium besylate injection, solution Estats Units - anglès - NLM (National Library of Medicine)

atracurium besylate- atracurium besylate injection, solution

sagent pharmaceuticals - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

ATRACURIUM BESYLATE injection, solution Estats Units - anglès - NLM (National Library of Medicine)

atracurium besylate injection, solution

sagent pharmaceuticals - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

ATRACURIUM BESYLATE injection, solution Estats Units - anglès - NLM (National Library of Medicine)

atracurium besylate injection, solution

meitheal pharmaceuticals inc. - atracurium besylate (unii: 40ax66p76p) (atracurium - unii:2gq1iry63p) - atracurium besylate injection is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. atracurium besylate is contraindicated in patients known to have a hypersensitivity to it. use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol.

CISATRACURIUM BESYLATE injection Estats Units - anglès - NLM (National Library of Medicine)

cisatracurium besylate injection

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarria